Connect with us

Australia

SUDA Pharmaceuticals to continue focus on cancer, insomnia treatments

SUDA Pharmaceuticals Ltd (ASX:SUD) is developing a radically new, first-in-class approach to the treatment of cancer using the drug anagrelide.

The company is also continuing to progress its short-term insomnia treatment, ZolpiMist, for which it is expecting to hear an outcome from its TGA submission in the fourth quarter of 2020.

As well, SUDA is developing products in conjunction with its partners, Sanofi (EPA:SAN), Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) and Cann Pharmaceutical Australia.

Cancer therapy licensing[hhmc]
SUDA had been progressing towards a proposed material licensing transaction in relation to a promising cancer therapy technology from a leading US cancer research institute and, on June 1, 2020, entered into a trading halt, to finalise these arrangements and the arrangements for a proposed capital raising.

The company engaged with ASX in relation to the application of ASX Listing Rules to the proposed transaction and had commissio..

SUDA Pharmaceuticals Ltd (ASX:SUD) is developing a radically new, first-in-class approach to the treatment of cancer using the drug anagrelide.

The company is also continuing to progress its short-term insomnia treatment, ZolpiMist, for which it is expecting to hear an outcome from its TGA submission in the fourth quarter of 2020.

As well, SUDA is developing products in conjunction with its partners, Sanofi (EPA:SAN), Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) and Cann Pharmaceutical Australia.

Cancer therapy licensing


SUDA had been progressing towards a proposed material licensing transaction in relation to a promising cancer therapy technology from a leading US cancer research institute and, on June 1, 2020, entered into a trading halt, to finalise these arrangements and the arrangements for a proposed capital raising.

The company engaged with ASX in relation to the application of ASX Listing Rules to the proposed transaction and had commissioned an independent expert to opine on the fairness and reasonableness of the proposed transaction.

On this basis, the board was confident that SUDA was in a position to be able to announce the proposed transaction and capital raising when the company was expected to come out of the trading halt on June 3, 2020.

Following SUDAs entry into a trading halt, ASX made a determination that the transaction is of the nature which would, in ASXs view, require the company to re-comply with Chapters 1 and 2 of the ASX Listing Rules for the purposes oRead More – Source

Continue Reading

Australia

THC Global targets product range expansion and entry into Asia Pacific, Latin America markets

THC Global Group Ltd (ASX:THC) plans to expand its product range and move into new territories in 2021 and beyond as it boosts production at its Southport facility to meet demand from New Zealand and Canadian markets.

The company is targeting to enter the Asia Pacific market in 2021+ with identified potential markets in Thailand, Malaysia, China, South Korea and Japan.

It also sees Latin American and other international opportunities to open with the pharma over-the-counter (OTC) cannabis scale-up.

THC Global operates across the cannabis supply chain, from cultivation, extraction, and direct patient and prescriber support services.

Milestones achieved[hhmc]
THC Global chairman Steven Xu said: “Over the past few months we have achieved several key milestones including launching our Canndeo medicines in Australia, supplying our first prescriptions and signing new production agreements.

“We look forward to building on top of these successes in the coming months and toward supporting ..

THC Global Group Ltd (ASX:THC) plans to expand its product range and move into new territories in 2021 and beyond as it boosts production at its Southport facility to meet demand from New Zealand and Canadian markets.

The company is targeting to enter the Asia Pacific market in 2021+ with identified potential markets in Thailand, Malaysia, China, South Korea and Japan.

It also sees Latin American and other international opportunities to open with the pharma over-the-counter (OTC) cannabis scale-up.

THC Global operates across the cannabis supply chain, from cultivation, extraction, and direct patient and prescriber support services.

Milestones achieved


THC Global chairman Steven Xu said: “Over the past few months we have achieved several key milestones including launching our Canndeo medicines in Australia, supplying our first prescriptions and signing new production agreements.

“We look forward to building on top of these successes in the coming months and toward supporting our target of 6,000 patients using a THC Global produced medicinal cannabis medicine by the end of 2020.”

Export markets


The company has secured agreements to export into Europe, New Zealand and Canada with effect from the third quarter of 2020, with the initial products focusing on CBD medicines range.

Its cannabis medicines are now competitively positioned for direct supply into Canada after receiving Health Canada licensing for Class I, II, III devices and Natural Health Products. Canada has an established market of more than 350,000 registered patients.

It has also inked deals with leading pharmaceutical distributors for New Zealand, as well as to provide prescriber support on cbdinfo.co.nz.

The first order from Medleaf Therapeutics in New Zealand has been received, with an initial supply of 2,250 bottles at $260,000, to be delivered on October 1, 2020.

This order is expected to support up to 800 patients in New Zealand on an ongoing basis.

THC Global is competitively positioned in the New Zealand market due to the requirement from October 2020 for the supply of all future medicines into the country, including future locally sourced medicines, to meet stringent registration requirements.

These include the provision of a six-month expiry date on medicines, which will be a significant time barrier on new market entrants based in New Zealand.

The European supply agreement with Germanys ACA Muller will see its products moving into more than 1,200 pharmacies across the European Union, with the first purchased supply into Europe expected in the fourth quarter this year.

THC Global is completing verification of Good Agricultural and Collecting Practice (GACP) supply for its external suppliers, which is a mandatory requirement for export into Europe.

The companys manufacturing facility is Good Manufacturing Practices (GMP) licensed by the Therapeutic Goods Administration in Australia and has reciprocal recognition across Europe in meeting EU-GMP requirements.

Domestic boost with rescheduling of CBD medicines


The company is also preparing for the rescheduling of CBD medicines in Australia, which is expected in the first quarter of 2021 and is readying products for the required specific Schedule 3 registration throughout 2020.

The Pharma Over-The-Counter (OTC) CBD medicines market will open supply to Australians via pharmacies without the need for a prescription.

THC believes it is the best placed to dominate this market with a global supply chain supplemented with large-scale, low-cost cultivation options and Australias largest capacity dedicated cannabis medicine manufacturing facility.

The value of the future Pharma OTC CBD medicines market has been projected to potentially exceed $200 million per year.

Spike in patient enquiries at Tetra Health


In June, Tetra Health, which THC Global acquired this year, received a 30% increase in patient inquiries and this trend is expected to continue.

In line with this, THC Global is expanding Tetra Healths clinical staff to ensure it can manage a continued increase in patients whilst ensuring a high level of patient support and care.

Tetra Health is a product-agnostic clinic, focused on medicinal cannabis prescribing, ongoing patient care and collecting real-world evidence on medicinal cannabis medicines.

It offers patients and prescribers a broad range of medicinal cannabis medicines, including THC Globals Canndeo medicines and medicines produced by THC Global uRead More – Source

Continue Reading

Australia

Peninsula Energy confirms strong director support for $40.3 million entitlement offer

Peninsula Energy Ltd (ASX:PEN) directors have acquired shares in the company via their participation in the recently completed $40.3 million entitlement offer.

Managing Director Wayne Heili acquired 1,290,476 shares, finance director/CFO David Coyne acquired 280,000 shares, non-executive chairman John Harrison added 37,800 shares and non-executive director Mark Wheatley bought 232,281 shares.

The newly acquired shares of Heili and Coyne also includes the vesting of previously approved Restricted Share Units and unlisted options to them.

Uranium production re-start strategy[hhmc]
The entitlement offer has allowed Peninsula to repay its existing term debt in full (principal amount of US$16.821 million (~$24.7 million) leaving the company cashed-up andRead More – Source

[contf]
[contfnew]

Proactiveinvestors
[contfnewc]
[contfnewc]

Peninsula Energy Ltd (ASX:PEN) directors have acquired shares in the company via their participation in the recently completed $40.3 million entitlement offer.

Managing Director Wayne Heili acquired 1,290,476 shares, finance director/CFO David Coyne acquired 280,000 shares, non-executive chairman John Harrison added 37,800 shares and non-executive director Mark Wheatley bought 232,281 shares.

The newly acquired shares of Heili and Coyne also includes the vesting of previously approved Restricted Share Units and unlisted options to them.

Uranium production re-start strategy


The entitlement offer has allowed Peninsula to repay its existing term debt in full (principal amount of US$16.821 million (~$24.7 million) leaving the company cashed-up andRead More – Source

Continue Reading

Australia

Infinity Lithium releases 3D video showcasing sustainable San José Lithium Project

Infinity Lithium Ltd (ASX:INF) has released a 3D video showing reproductions of what the sustainable San Jose Valdeflórez Lithium Project in Cáceres, Spain, will look like.

The video, which lasts for about two minutes, showcases how the project is designed to guarantee the protection of the citys ecosystem with the responsible use of water and health protection initiatives.

This digital recreation shows details of the mining area, the industrial plant and the tailings as well as the continuous rehabilitation of the site.

[embedded content]

Europe's second-largest lithium deposit[hhmc]
San José Valdeflórez, which is the second-largest lithium deposit in the European Union, is set to put Cáceres on the map of the electric vehicle (EV) sector.

INF is working to develop a sustainable project that offers opportunities for the strategic development of a fully integrated supply chain for EVs in Europe

The video states Cáceres has the opportunity to set an example globally with a te..

Infinity Lithium Ltd (ASX:INF) has released a 3D video showing reproductions of what the sustainable San Jose Valdeflórez Lithium Project in Cáceres, Spain, will look like.

The video, which lasts for about two minutes, showcases how the project is designed to guarantee the protection of the citys ecosystem with the responsible use of water and health protection initiatives.

This digital recreation shows details of the mining area, the industrial plant and the tailings as well as the continuous rehabilitation of the site.

Europe's second-largest lithium deposit


San José Valdeflórez, which is the second-largest lithium deposit in the European Union, is set to put Cáceres on the map of the electric vehicle (EV) sector.

INF is working to develop a sustainable project that offers opportunities for the strategic development of a fully integrated supply chain for EVs in Europe

The video states Cáceres has the opportunity to set an example globally with a technology that is already changing the world – electric mobility.

Lithium supply strategy


Infinity recently strengthened its European lithium supply strategy by executing binding agreementRead More – Source

Continue Reading

Trending